Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 10:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diabetes Mellitus Type I Clear all
Completed Not applicable Interventional

Let's Empower and Prepare Young Adults With Type 1 Diabetes

NCT02807155
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Transition Empowerment Program, Transition Empowerment Program (TEP) + Diabetes Wellness Council (DWC), Online Transition Empowement Program Access
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
19 Years to 25 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Jun 10, 2026, 10:46 PM EDT
Completed Phase 2 Interventional

Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis

NCT01452815
View directory record Official record
Conditions
Gastroparesis, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Placebo, 10mg TZP-102, 20mg TZP-102
Drug
Lead sponsor
Tranzyme, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
31
States / cities
Huntsville, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2013 · Synced Jun 10, 2026, 10:46 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

NCT05824975
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
Interventions
GI-102 subcutaneous (SC), GI-102, doxorubicin, paclitaxel, bevacizumab, eribulin, trastuzumab deruxtecan (T-DXd), pembrolizumab
Drug
Lead sponsor
GI Innovation, Inc.
Industry
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2024 · Synced Jun 10, 2026, 10:46 PM EDT
Completed Not applicable Interventional

Study of A Cell-Phone System to Improve Health of Youth With Diabetes

NCT02280564
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
health coaching with technology support
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 16 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Aurora, Colorado • Raleigh, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Jun 10, 2026, 10:46 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones.

NCT03668808
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin Degludec, Insulin Glargine, TRESIBA® FLEXTOUCH®, LANTUS® SOLOSTAR® INSULIN PEN
Drug · Device
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Santa Barbara, California • Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Jun 10, 2026, 10:46 PM EDT
Recruiting Not applicable Interventional

Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes

NCT05653518
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Tandem t:slim X2 with Control-IQ Technology, Sensor augmented pump (SAP) therapy
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 40 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jun 10, 2026, 10:46 PM EDT
Withdrawn Phase 2 Interventional

Effect of GABA Supplementation in the Progression of Type 1 Diabetes in Children

NCT01561508
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
gamma-amino-butyric acid, Xylitol
Drug · Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
8 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 23, 2012 · Synced Jun 10, 2026, 10:46 PM EDT
Completed Not applicable Interventional Results available

Prepivotal Omnipod Horizon™ Automated Glucose Control System

NCT04176731
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Omnipod Horizon™ Automated Glucose Control System
Device
Lead sponsor
Insulet Corporation
Industry
Eligibility
6 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Palo Alto, California • Denver, Colorado • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Jun 10, 2026, 10:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)

NCT01275131
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin aspart, Recombinant human hyaluronidase PH20 (rHuPH20)
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Jun 10, 2026, 10:46 PM EDT
Completed Not applicable Interventional Results available

Sleep Promotion to Improve Diabetes Management in Adolescents With T1D

NCT02786953
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Sleep Promotion
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
13 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Jun 10, 2026, 10:46 PM EDT
Completed Not applicable Interventional Results available

A Sleep Intervention in Type 1 Diabetes

NCT03617770
View directory record Official record
Conditions
Short Sleep Phenotype, Type1diabetes
Interventions
Sleep Opt-In, Healthy Living
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Jun 10, 2026, 10:46 PM EDT
Completed Phase 1 Interventional

Evaluation of Extended Infusion Set Wear Using Medtronic Extended Wear Sof-set Infusion Set

NCT02687256
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Extended Wear infusion set, Standard Infusion set, Heparin
Device · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Jun 10, 2026, 10:46 PM EDT
Recruiting Phase 2 Interventional

SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

NCT07187531
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
High Dose SAB-142, Low Dose SAB-142, Placebo
Drug · Other
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
5 Years to 40 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
23
States / cities
San Francisco, California • San Jose, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 10, 2026, 10:46 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Liraglutide in the Treatment of Type 1 Diabetes Mellitus

NCT01722266
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Liraglutide, Placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Jun 10, 2026, 10:46 PM EDT
Completed Phase 3 Interventional Results available

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)

NCT02227862
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Mylan's insulin glargine, Lantus®
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
72
States / cities
Bell Gardens, California • Fresno, California • Greenbrae, California + 64 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Jun 10, 2026, 10:46 PM EDT
Active, not recruiting Phase 1 Interventional

An Immunotherapy Vaccine (PIpepTolDC) for the Treatment of Patients With Type 1 Diabetes

NCT04590872
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Tolerogenic Dendritic Cell Vaccine
Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jun 10, 2026, 10:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Measurement of Glucose Metabolism in Humans Using Magnetic Resonance at 4 Tesla. Substudy: Hypoglycemia Unawareness

NCT00793741
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia Unawareness
Interventions
somatostatin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Jun 10, 2026, 10:46 PM EDT
Recruiting Phase 2 Interventional

Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment

NCT06411210
View directory record Official record
Conditions
Diabetes type1, Obesity
Interventions
Semaglutide Pen Injector, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 30 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Jun 10, 2026, 10:46 PM EDT
Completed Phase 3 Interventional Results available

Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus

NCT00419562
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Oral Insulin, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
3 Years to 45 Years
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
13
States / cities
San Francisco, California • Stanford, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Jun 10, 2026, 10:46 PM EDT
Active, not recruiting Phase 1 Interventional

Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen

NCT00706420
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Islet Transplantation + Immunosuppression, Islet cell transplantation
Procedure · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Jun 10, 2026, 10:46 PM EDT
Completed Not applicable Interventional Results available

Feasibility Studies of Personalized Closed Loop

NCT04203823
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Cloud-based Digital Twin and Meal Prediction algorithms
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
2 Years to 80 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Loma Linda, California • Walnut Creek, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Jun 10, 2026, 10:46 PM EDT
Completed Phase 4 Interventional Results available

Use of Santyl in Diabetic Foot Ulcers

NCT02581488
View directory record Official record
Conditions
Diabetic Foot, Foot Ulcer, Diabetic
Interventions
Santyl, Product containing silver
Biological · Other
Lead sponsor
Smith & Nephew, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
11
States / cities
Sylmar, California • Melbourne, Florida • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Jun 10, 2026, 10:46 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma

NCT02535078
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Tebentafusp (IMCgp100)
Drug
Lead sponsor
Immunocore Ltd
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
4
States / cities
Los Angeles, California • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Jun 10, 2026, 10:46 PM EDT
Completed Phase 1 Interventional

Study To Assess the Pharmacokinetics of AZD1656 During Coadministration With Simvastatin

NCT01096940
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
AZD1656, simvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2010 · Synced Jun 10, 2026, 10:46 PM EDT